How to buy Nevro stock | $119.17

Nevro Corp is a medical devices business based in the US. Nevro shares (NVRO) are listed on the NYSE and all prices are listed in US Dollars. Nevro employs 843 staff and has a trailing 12-month revenue of around 0.00.

Nevro stock price (NYSE: NVRO)

Use our graph to track the performance of NVRO stocks over time.

Nevro shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$119.17
52-week range	$99.54 - $188.14
50-day moving average	$120.51
200-day moving average	$141.25
Wall St. target price	$139.62
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.97

Buy Nevro shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Nevro stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nevro price performance over time

Historical closes compared with the close of $119.17 from 2021-10-20

1 week (2021-10-14)	2.19%
1 month (2021-09-21)	-3.72%
3 months (2021-07-21)	-22.75%
6 months (2021-04-21)	-26.01%

1 year (2020-10-20)	-20.85%
2 years (2019-10-18)	40.20%
3 years (2018-10-19)	136.92%
5 years (2016-10-20)	20.23%

Nevro financials

Revenue TTM	$409.1 million
Gross profit TTM	$249.9 million
Return on assets TTM	-3.95%
Return on equity TTM	-18.63%
Profit margin	-16.69%
Book value	$10.28
Market capitalisation	$4.1 billion

TTM: trailing 12 months

Shorting Nevro shares

There are currently 2.3 million Nevro shares held short by investors – that's known as Nevro's "short interest". This figure is 3.8% down from 2.4 million last month.

There are a few different ways that this level of interest in shorting Nevro shares can be evaluated.

Nevro's "short interest ratio" (SIR)

Nevro's "short interest ratio" (SIR) is the quantity of Nevro shares currently shorted divided by the average quantity of Nevro shares traded daily (recently around 392260.27164686). Nevro's SIR currently stands at 5.89. In other words for every 100,000 Nevro shares traded daily on the market, roughly 5890 shares are currently held short.

However Nevro's short interest can also be evaluated against the total number of Nevro shares, or, against the total number of tradable Nevro shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nevro's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Nevro shares in existence, roughly 70 shares are currently held short) or 0.0675% of the tradable shares (for every 100,000 tradable Nevro shares, roughly 68 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nevro.

Find out more about how you can short Nevro stock.

Nevro share dividends

We're not expecting Nevro to pay a dividend over the next 12 months.

Have Nevro's shares ever split?

Nevro's shares were split on a 1:24 basis on 5 November 2014. So if you had owned 24 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nevro shares – just the quantity. However, indirectly, the new 2300% higher share price could have impacted the market appetite for Nevro shares which in turn could have impacted Nevro's share price.

Nevro share price volatility

Over the last 12 months, Nevro's shares have ranged in value from as little as $99.54 up to $188.14. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Nevro's is 1.0571. This would suggest that Nevro's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Nevro overview

Nevro Corp. , a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California. .

Frequently asked questions

What percentage of Nevro is owned by insiders or institutions?
Currently 1.723% of Nevro shares are held by insiders and 112.076% by institutions. How many people work for Nevro?
Latest data suggests 843 work at Nevro. When does the fiscal year end for Nevro?
Nevro's fiscal year ends in December. Where is Nevro based?
Nevro's address is: 1800 Bridge Parkway, Redwood City, CA, United States, 94065 What is Nevro's ISIN number?
Nevro's international securities identification number is: US64157F1030 What is Nevro's CUSIP number?
Nevro's Committee on Uniform Securities Identification Procedures number is: 64157F103